Precision BioSciences DTIL 深 沪
等待开盘 08-25 09:30:00 美东时间
8.45
-0.400
-4.52%
华盛通- 最 高8.82
- 今 开8.82
- 成交量 23.28万股
- 最 低 8.36
- 昨 收 8.85
- 总市值 2.33亿
- 52周最高 9.62
- 市盈率 静 --
- 换手率 0.84%
- 52周最低 3.53
- 委 比 63.49%
- 总股本 2760.16万
- 历史最高 710.10
- 量 比 0.67
- 振 幅 5.20%
- 历史最低 3.53
- 每 手 1
- 风险率 1.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Precision BioSciences Begins First DMD Gene-Editing Trial
The latest update is out from Precision BioSciences ( ($DTIL) ). On August 24, ...
08-24 19:49
iECURE Announces Updated Safety And Metabolic Control Data From Phase 1/2 Trial Of ECUR-506 In Neonatal-Onset OTC Deficiency To Be Presented August 27 At SSIEM Symposium
iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.
08-20 20:03
Precision BioSciences调整高管团队，助力临床项目冲刺关键里程碑
临床阶段基因编辑公司Precision BioSciences （Nasdaq： DTIL） 今日宣布对其高级领导团队进行调整，旨在为核心项目的下一阶段临床...
07-27 21:53
Precision BioSciences Announces Key Executive Leadership Changes
Precision BioSciences ( ($DTIL) ) has issued an announcement. On July 23, 2026,...
07-27 19:58
Precision BioSciences announces key management changes
Precision BioSciences (DTIL) announced changes to its senior leadership team as the gene-editing company prepares to advance its lead clinical programs. Alex Kelly will be promoted from CFO to the new...
07-27 19:18
Precision BioSciences Promotes Alex Kelly To COO And Naresh Tanna To CFO, Effective August 1, 2026
– Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g...
07-27 19:10
Precision BioSciences向三名新员工授予激励股权
临床阶段基因编辑公司Precision BioSciences周五宣布，其董事会薪酬委员会已于7月5日批准向三名新入职员工授予总计114，622股限制性股票...
07-10 21:15
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.
07-09 18:03
